用科技之精确，证验传统之精深。通过构建现代化创新体系，研发团队进一步对《伤寒论》《金匮要 略》等经典典籍中的方剂进行转化研究，运用现代组学技术深度解析，搭建起拥有12万条古方数据的知 识图谱，并借助AI算法挖掘潜在功效成分群，提升古代经典名方转化率，远超行业平均水平。与此同 时，针对中药复杂成分体系的质控难题，康缘药业首创"功效成分群"质控体系，采用"化学指纹图谱— 生物活性评价—临床疗效验证"三位一体评价模型，将质控指标从传统的3—5个大幅提升到动态监测的 30—50个功效成分群，进而形成一套完善的质控体系。 秉持"让中药回归到药物自身属性——安全、有效、质量均一"的研发理念，康缘药业以临床价值为导 向，聚焦病毒性感染性疾病、妇科疾病等中医药优势领域，打造系统完善的全流程研发平台，目前拥有 59个中药新药，近五年累计获批6个中药新药，获批中药创新药总数位居行业之首。其中，筋骨止痛凝 胶是近十年来首个上市的中药凝胶剂；银翘清热片是2020年新药品注册管理办法实施后首个获批的1.1 类创新中药；苓桂术甘颗粒则是首个按古代经典名方目录管理的3.1类中药新药，入选2022年度中医药 十大学术进展。 苓桂术甘汤、四逆 ...

Core Viewpoint - The Chinese medicine sector is experiencing a positive trend, with the Zhongzheng Traditional Chinese Medicine Index showing an increase, driven by policy benefits and the rapid modernization of classic formulas into contemporary medicine [1][2]. Group 1: Market Performance - As of November 12, 2025, the Zhongzheng Traditional Chinese Medicine Index (930641) rose by 0.57%, with notable increases in constituent stocks such as Zhongsheng Pharmaceutical (002317) up by 10.02% and Panlong Pharmaceutical (002864) up by 10.00% [1]. - The Chinese Medicine ETF (159647) also saw a rise of 0.29%, marking its sixth consecutive increase, with the latest price reported at 1.05 yuan [1]. Group 2: Industry Trends - There is a continuous release of policy benefits, leading to an accelerated layout of classic formulas by Chinese medicine companies, with products like Loquat Lung Cleansing Granules and Warming Meridian Decoction being rapidly transformed into modern formulations [1]. - Guojin Securities identifies the main investment opportunities in the pharmaceutical sector for 2025 as the innovation drug theme and the reversal of challenges in the left-side sector, emphasizing the potential of dual/multi-antibody drugs and addressing unmet clinical needs in chronic disease medications [1]. Group 3: Index Composition - The Zhongzheng Traditional Chinese Medicine Index includes companies involved in the production and sales of traditional Chinese medicine, with the top ten weighted stocks accounting for 54.92% of the index as of October 31, 2025 [2].